



Canada's source for  
HIV and hepatitis C  
information

La source canadienne  
de renseignements sur  
le VIH et l'hépatite C

## Fact Sheets

### Infections

[Cytomegalovirus disease \(CMV\)](#)  
[Mycobacterium avium complex \(MAC\)](#)  
[Pneumocystis pneumonia \(PCP\)](#)  
[Progressive multifocal leukoencephalopathy \(PML\)](#)  
[Toxoplasmosis](#)  
[Tuberculosis](#)  
[Yeast infections—vaginal](#)

### Sexually Transmitted Infections

[Chlamydia](#)  
[Genital herpes](#)  
[Gonorrhea](#)  
[Hepatitis A](#)  
[Hepatitis B](#)  
[HPV, cervical dysplasia and cervical cancer](#)  
[HPV, anal dysplasia and anal cancer](#)  
[Syphilis](#)

### Sexually Transmitted Infections (Key Messages for Clients)

[What you need to know about chlamydia](#)  
[What you need to know about genital herpes](#)  
[What you need to know about gonorrhea](#)  
[What you need to know about hepatitis A](#)  
[What you need to know about hepatitis B](#)  
[What you need to know about human papillomavirus \(HPV\)](#)  
[What you need to know about syphilis](#)

### Cancers

[HPV, anal dysplasia and anal cancer](#)  
[HPV, cervical dysplasia and cancer](#)  
[Kaposi's sarcoma \(KS\)](#)  
[Lymphoma](#)

### Hepatitis

[Daclatasvir \(Daklinza\)](#)  
[Epclusa \(velpatasvir + sofosbuvir\)](#)  
[Harvoni \(ledipasvir + sofosbuvir\)](#)  
[Hepatitis A](#)  
[Hepatitis B](#)  
[Holkira Pak \(dasabuvir + ombitasvir/paritaprevir/ritonavir\)](#)  
[Ribavirin](#)  
[Simeprevir \(Galexos\)](#)  
[Sofosbuvir \(Sovaldi\)](#)  
[Technivie \(ombitasvir/paritaprevir/ritonavir\)](#)  
[The epidemiology of hepatitis C in Canada](#)  
[Zepatier \(elbasvir + grazoprevir\)](#)

For more information, see [Hepatitis C](#)

## Other Health Conditions

[HIV and cardiovascular disease](#)

For more information, see [A Practical Guide to a Healthy Body for People Living with HIV](#) and [A Practical Guide to HIV Drug Side Effects](#)

## Prevention

[Condoms for the prevention of HIV and STI transmission](#)

[Oral pre-exposure prophylaxis \(PrEP\)](#)

[Post-exposure prophylaxis \(PEP\)](#)

[HIV treatment and an undetectable viral load to prevent HIV transmission](#)

[Penile circumcision to reduce the risk of HIV infection](#)

[Immunizations \(vaccinations\) for people with HIV](#)

## Women and HIV

[HPV, cervical dysplasia and cancer](#)

[The epidemiology of HIV in women](#)

[Yeast infections—vaginal](#)

For more information, see [A Practical Guide to a Healthy Body for People Living with HIV](#) and [A Practical Guide to HIV Drug Side Effects](#)

## HIV Drug Treatment

### Co-formulations

[Atripla](#)

[Combivir](#)

[Complera](#)

[Descovy](#)

[Genvoya](#)

[Kivexa](#)

[Prezcobix](#)

[Stribild](#)

[Triumeq](#)

[Trizivir](#)

[Truvada](#)

### Entry inhibitors

[Maraviroc \(Celsentri\)](#)

### Fusion inhibitors

[T-20 \(enfuvirtide, Fuzeon\)](#)

### Integrase inhibitors

[Dolutegravir \(Tivicay\)](#)

[Raltegravir \(Isentress\)](#)

### Non-nukes

[Delavirdine \(Rescriptor\)](#)

[Efavirenz \(Sustiva\)](#)

[Etravirine \(Intelence\)](#)  
[Nevirapine \(Viramune\)](#)  
[Ralpivirine \(Edurant\)](#)

## **Nukes**

[3TC \(lamivudine, Epivir\)](#)  
[Abacavir \(Ziagen\)](#)  
[AZT \(zidovudine, Retrovir\)](#)  
[d4T \(stavudine, Zerit\)](#)  
[ddI \(didanosine, Videx EC\)](#)  
[Tenofovir \(Viread\)](#)

## **Protease inhibitors**

[Atazanavir \(Reyataz\)](#)  
[Darunavir \(Prezista\)](#)  
[Fosamprenavir \(Telzir\)](#)  
[Indinavir \(Crixivan\)](#)  
[Kaletra \(Lopinavir/ritonavir\)](#)  
[Nelfinavir \(Viracept\)](#)  
[Ritonavir \(Norvir\)](#)  
[Saquinavir \(Invirase\)](#)  
[Tipranavir \(Aptivus\)](#)

## **Testing**

[Abacavir hypersensitivity screening](#)  
[The HIV testing process](#)  
[HIV testing technologies](#)  
[HIV viral load testing](#)  
[Tropism testing](#)

## **Vitamins and Supplements**

[Acetyl-L-carnitine and L-carnitine](#)  
[NAC \(N-acetyl-cysteine\)](#)

For more information, see [A Practical Guide to Herbal Therapies for People Living With HIV](#) and [A Practical Guide to Nutrition for People Living with HIV](#)

## **HIV and Hepatitis C in Canada**

[The epidemiology of hepatitis C in Canada](#)  
[The epidemiology of HIV in Canada](#)  
[The epidemiology of HIV in females](#)  
[The epidemiology of HIV in gay men and other men who have sex with men](#)  
[The epidemiology of HIV in people who inject drugs in Canada](#)  
[The epidemiology of HIV in youth](#)

## **Street/Recreational Drugs**

[Recreational drugs and HIV](#)

## Produced By:



Canada's source for  
HIV and hepatitis C  
information

555 Richmond Street West, Suite 505, Box 1104  
Toronto, Ontario M5V 3B1 Canada  
Phone: 416.203.7122  
Toll-free: 1.800.263.1638  
Fax: 416.203.8284  
www.catie.ca  
Charitable registration number: 13225 8740 RR

## Disclaimer

Decisions about particular medical treatments should always be made in consultation with a qualified medical practitioner knowledgeable about HIV- and hepatitis C-related illness and the treatments in question.

CATIE provides information resources to help people living with HIV and/or hepatitis C who wish to manage their own health care in partnership with their care providers. Information accessed through or published or provided by CATIE, however, is not to be considered medical advice. We do not recommend or advocate particular treatments and we urge users to consult as broad a range of sources as possible. We strongly urge users to consult with a qualified medical practitioner prior to undertaking any decision, use or action of a medical nature.

CATIE endeavours to provide the most up-to-date and accurate information at the time of publication. However, information changes and users are encouraged to ensure they have the most current information. Users relying solely on this information do so entirely at their own risk. Neither CATIE nor any of its partners or funders, nor any of their employees, directors, officers or volunteers may be held liable for damages of any kind that may result from the use or misuse of any such information. Any opinions expressed herein or in any article or publication accessed or published or provided by CATIE may not reflect the policies or opinions of CATIE or any partners or funders.

Information on safer drug use is presented as a public health service to help people make healthier choices to reduce the spread of HIV, viral hepatitis and other infections. It is not intended to encourage or promote the use or possession of illegal drugs.

## Permission to Reproduce

This document is copyrighted. It may be reprinted and distributed in its entirety for non-commercial purposes without prior permission, but permission must be obtained to edit its content. The following credit must appear on any reprint: *This information was provided by CATIE (the Canadian AIDS Treatment Information Exchange). For more information, contact CATIE at 1.800.263.1638.*

© CATIE

Production of this content has been made possible through a financial contribution from the Public Health Agency of Canada.

Available online at:  
<http://www.catie.ca/en/fact-sheets>